CNS Summit Series: Schizophrenia, Clinical Trials and Hope, with Dr. David Walling of Cenexel CNS

In this special edition of The Syneos Health Podcast, host Dr. Alexandria Wise celebrates 15 years of innovation with CNS Summit by interviewing Dr. David Walling, Chief Clinical Officer at CenExel CNS. Recorded from the floor of CNS Summit 2024, the conversation dives into Dr. Walling’s career journey, his passion for advancing care for individuals with schizophrenia, and the evolution of clinical trials over the past two decades.Dr. Walling shares insights into CenExel’s mission as a “Center of Excellence” for clinical research and reflects on his early work with schizophrenia patients, from the development of atypical antipsychotics in the 1990s to today’s cutting-edge therapies like KarXT, a newly FDA-approved medication with a novel mechanism of action. The discussion highlights the increasing importance of patient-centered approaches, the integration of patient voices in clinical trial design, and the promise of innovative treatments that address not only positive symptoms but also negative symptoms and cognitive deficits in schizophrenia.Tune in for an engaging and hopeful exploration of advancements in CNS disorders, the challenges of drug development, and the strides being made toward improving patient quality of life. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].